AN2 Therapeutics (ANTX) Total Current Liabilities (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Total Current Liabilities for 6 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities changed N/A year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (changed N/A YoY), while the FY2025 annual figure was $8.7 million, down 14.83% from the prior year.
• Total Current Liabilities slipped to $5.6 million in Q1 2026 per ANTX's latest filing, from $8.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $14.8 million in Q3 2023 and bottomed at $4.1 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $8.7 million across 5 years, with a median of $8.6 million in 2023.
• Annual changes were most pronounced in 2023 — Total Current Liabilities soared 234.81% — and 2024, when it plunged 32.5%.
• AN2 Therapeutics' Total Current Liabilities stood at $7.2 million in 2022, then jumped by 95.42% to $14.0 million in 2023, then slipped by 27.1% to $10.2 million in 2024, then fell by 14.83% to $8.7 million in 2025, then plunged by 36.22% to $5.6 million in 2026.
• Business Quant data shows ANTX's Total Current Liabilities at $5.6 million in Q1 2026, $8.7 million in Q4 2025, and $10.2 million in Q4 2024.